BE1014078A6 - Composition a base de cefuroxime axetil et son utilisation. - Google Patents

Composition a base de cefuroxime axetil et son utilisation. Download PDF

Info

Publication number
BE1014078A6
BE1014078A6 BE2002/0667A BE200200667A BE1014078A6 BE 1014078 A6 BE1014078 A6 BE 1014078A6 BE 2002/0667 A BE2002/0667 A BE 2002/0667A BE 200200667 A BE200200667 A BE 200200667A BE 1014078 A6 BE1014078 A6 BE 1014078A6
Authority
BE
Belgium
Prior art keywords
cefuroxime axetil
composition based
composition
constitutive
lipids
Prior art date
Application number
BE2002/0667A
Other languages
English (en)
Inventor
Mathilde Ibanez Fernandez
Emilio Sanz Garriz
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of BE1014078A6 publication Critical patent/BE1014078A6/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)

Abstract

Composition comprenant du céfuroxime axétil sous forme particulaire, les particules étant enrobées d'enrobages constitutifs d'un lipide ou mélange de lipides qui sont insolubles dans l'eau, la composition comprenant de plus un système d'édulcorant et un modificateur de texture qui servent à masquer le goût amer du céfuroxime axétil lors de l'administration orale.
BE2002/0667A 2001-11-23 2002-11-21 Composition a base de cefuroxime axetil et son utilisation. BE1014078A6 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01500277 2001-11-23

Publications (1)

Publication Number Publication Date
BE1014078A6 true BE1014078A6 (fr) 2003-03-04

Family

ID=8183502

Family Applications (2)

Application Number Title Priority Date Filing Date
BE2002/0668A BE1015217A5 (fr) 2001-11-23 2002-11-21
BE2002/0667A BE1014078A6 (fr) 2001-11-23 2002-11-21 Composition a base de cefuroxime axetil et son utilisation.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BE2002/0668A BE1015217A5 (fr) 2001-11-23 2002-11-21

Country Status (34)

Country Link
US (1) US20030161888A1 (fr)
EP (1) EP1446126B1 (fr)
JP (1) JP3497503B2 (fr)
KR (1) KR100979328B1 (fr)
CN (1) CN1297274C (fr)
AT (1) ATE473006T1 (fr)
AU (2) AU2002338950A1 (fr)
BE (2) BE1015217A5 (fr)
BR (1) BR0204767A (fr)
CA (1) CA2408198C (fr)
CH (1) CH693982A5 (fr)
CO (1) CO5580783A2 (fr)
CY (1) CY1110778T1 (fr)
CZ (1) CZ12993U1 (fr)
DE (3) DE60236952D1 (fr)
DK (1) DK1446126T3 (fr)
ES (2) ES2201932B2 (fr)
FR (1) FR2832635B1 (fr)
GB (1) GB2383536B (fr)
GR (1) GR1004522B (fr)
HR (2) HRP20020924A2 (fr)
HU (1) HUP0204026A3 (fr)
IL (2) IL161972A0 (fr)
IT (1) ITMI20022470A1 (fr)
MX (1) MXPA02011561A (fr)
NO (1) NO335273B1 (fr)
NZ (1) NZ533092A (fr)
PL (1) PL205325B1 (fr)
PT (1) PT1446126E (fr)
RU (1) RU2241460C2 (fr)
SI (1) SI1446126T1 (fr)
TR (1) TR200202559A2 (fr)
WO (1) WO2003043638A1 (fr)
ZA (1) ZA200209473B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) * 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
ATE516019T1 (de) 2004-05-11 2011-07-15 Egalet Ltd Quellbare dosierform mit gellan-gummit
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP4972311B2 (ja) * 2004-12-15 2012-07-11 あすか製薬株式会社 イソソルビドの苦味が軽減された経口製剤及びその製造方法
JP2012107060A (ja) * 2004-12-15 2012-06-07 Aska Pharmaceutical Co Ltd イソソルビドの苦味が軽減された経口製剤及びその製造方法
DE102005019458A1 (de) 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
CN101756906B (zh) * 2009-11-02 2011-11-16 严洁 盐酸头孢卡品酯颗粒的药物组合物及其制备方法
AU2010325746B2 (en) 2009-12-02 2016-02-25 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them
WO2011085181A1 (fr) * 2010-01-08 2011-07-14 Eurand, Inc. Composition de topiramate à goût masqué et comprimé à délitement oral l'incluant
EP2566458B1 (fr) 2010-05-04 2015-08-05 Mahmut Bilgic Formulations pharmaceutiques comprenant du céfuroxime axétil
JP5853461B2 (ja) * 2010-07-30 2016-02-09 大正製薬株式会社 内服液剤
WO2013024373A1 (fr) * 2011-08-12 2013-02-21 Dhanuka Laboratories Ltd. Composition pharmaceutique comprenant du céfuroxime
CN102440960A (zh) * 2011-09-01 2012-05-09 山东鲁抗医药股份有限公司 一种头孢呋辛酯干混悬剂药物组合物及其制备方法
CA2852912A1 (fr) * 2011-10-31 2013-05-10 Glaxosmithkline Intellectual Property Limited Formulation de pazopanib
CN108338936A (zh) * 2017-01-23 2018-07-31 刘全忠 敏感皮肤防护露的制备及使用
JP2023146766A (ja) * 2022-03-29 2023-10-12 味の素株式会社 造粒物およびその製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
CA1094545A (fr) * 1976-02-16 1981-01-27 Michael Gregson Traduction non-disponible
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8320520D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US4992276A (en) * 1988-12-14 1991-02-12 Warner-Lambert Company Antiseptic compositions containing hexahydro-5-pyrimidinamine compounds and thymol and methods for preparing same
ES2194863T3 (es) * 1992-11-30 2003-12-01 Kv Pharm Co Materiales farmaceuticos con enmascarado de sabor.
WO1994025006A1 (fr) * 1993-04-26 1994-11-10 Affinity Biotech, Inc. Compositions pharmaceutiques masquant le gout et leurs procedes de production
IT1277426B1 (it) * 1995-08-03 1997-11-10 Acs Dobfar Spa Forma cristallina biodisponibile del cefuroxima axetil
NZ299077A (en) * 1996-07-26 1998-06-26 Apotex Inc Preparation of amorphous cefuroxime axetil (a cephalosporin derivative) by dissolving crystalline cefuroxim axetil in a highly polar solvent, typically dmso and/or dmf
JP2002511777A (ja) * 1996-10-28 2002-04-16 ゼネラル ミルズ，インコーポレイテッド 調放性粒子の埋包およびカプセル化
CA2209868C (fr) * 1997-08-15 2001-08-14 Bernard Charles Sherman Compositions pharmaceutiques a base de cefuroxime axetil
GB9726781D0 (en) * 1997-12-19 1998-02-18 Glaxo Group Ltd Pharmaceutical composition
WO1999033445A1 (fr) 1997-12-29 1999-07-08 The Procter & Gamble Company Composition de comprime
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
BR0011345A (pt) * 1999-06-11 2002-04-23 Ranbaxy Lab Ltd Composições com sabor mascarado

Also Published As

Publication number Publication date
CN1297274C (zh) 2007-01-31
CA2408198A1 (fr) 2003-02-02
PL357259A1 (en) 2003-06-02
NO335273B1 (no) 2014-11-03
CH693982A5 (de) 2004-05-28
HRP20020924A2 (en) 2003-10-31
ES2201932A1 (es) 2004-03-16
HUP0204026A3 (en) 2004-09-28
HU0204026D0 (en) 2003-01-28
AU2002302147B2 (en) 2005-01-20
BR0204767A (pt) 2003-09-16
JP3497503B2 (ja) 2004-02-16
IL161972A0 (en) 2005-11-20
ITMI20022470A1 (it) 2003-05-24
DK1446126T3 (da) 2010-10-11
ES2347536T3 (es) 2010-11-02
DE60236952D1 (de) 2010-08-19
ATE473006T1 (de) 2010-07-15
ZA200209473B (en) 2003-06-10
NZ533092A (en) 2006-02-24
GR1004522B (el) 2004-04-06
PT1446126E (pt) 2010-09-24
RU2241460C2 (ru) 2004-12-10
IL161972A (en) 2009-06-15
US20030161888A1 (en) 2003-08-28
SI1446126T1 (sl) 2010-10-29
HUP0204026A2 (hu) 2003-08-28
GB2383536B (en) 2003-11-19
FR2832635B1 (fr) 2006-04-21
WO2003043638A1 (fr) 2003-05-30
CA2408198C (fr) 2004-03-09
GR20020100506A (el) 2003-07-16
PL205325B1 (pl) 2010-04-30
NO20042620L (no) 2004-06-22
DE20218068U1 (de) 2003-03-27
EP1446126B1 (fr) 2010-07-07
DE10254412A1 (de) 2003-06-12
CN1421206A (zh) 2003-06-04
CZ12993U1 (cs) 2003-02-10
CY1110778T1 (el) 2015-06-10
TR200202559A2 (tr) 2003-06-23
ES2201932B2 (es) 2005-03-16
HRP20020923A2 (en) 2003-10-31
CO5580783A2 (es) 2005-11-30
AU2002338950A1 (en) 2003-06-10
GB2383536A (en) 2003-07-02
GB0227215D0 (en) 2002-12-24
KR20050044590A (ko) 2005-05-12
BE1015217A5 (fr) 2004-11-09
MXPA02011561A (es) 2005-07-13
FR2832635A1 (fr) 2003-05-30
KR100979328B1 (ko) 2010-08-31
EP1446126A1 (fr) 2004-08-18
JP2003160493A (ja) 2003-06-03

Similar Documents

Publication Publication Date Title
BE1014078A6 (fr) Composition a base de cefuroxime axetil et son utilisation.
FR2655266B1 (fr) Compositions pharmaceutiques a base de cimetidine.
ZA991408B (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.
TR199600498A2 (tr) S(+)-ibuprofen'in oral formülasyonlari.
EP0611790A3 (en) Polytetrafluoroethylene porous film and preparation and use thereof.
CA2103829A1 (fr) Conjugues peg-interferon
FI945912A0 (fi) Proteinoidikantajat ja menetelmät niiden valmistamiseksi sekä niiden käyttö
HUT77359A (hu) Aranyérellenes készítmények és alkalmazásuk
FI962952A7 (fi) Delta 12,13-iso-taksolianalogit, niiden antineoplastinen käyttö ja nii tä sisältävät farmaseuttiset koostumukset
PT999843E (pt) Composicoes farmaceuticas contendo vitamina d e calcio, sua preparacao e uso terapeutico
ES2140489T3 (es) Receptor de interferona soluble, su preparacion y su uso.
IT9021157A0 (it) "catalizzatore di deidroisomerizzazione e suo uso nella preparazione di isobutene da n-butano"
ZA964985B (en) N-[1,4-diazabicyclo[2.2.2]oct-2-yl)methyl]benzamide derivatives their preparation and their applications in therapeutics
IT9021041A0 (it) "copolimero a blocchi, procedimenti per la sua preparazione e suo impiego"
WO1999033989A3 (fr) Mutants rantes et leurs applications therapeutiques
RU92004553A (ru) Стабилизированная фармацевтическая композиция на основе рекомбинантного, негликозилированного 1l-2 человека в восстановленном виде и способ ее получения
FR2684848B1 (fr) Utilisation du glucomannane pour la preparation d'une gelee orale a effet de satiete et gelee orale comprenant du glucomannane a effet de satiete ainsi obtenue.
FR2768731B1 (fr) Derives insatures en position -4 du 6-tert-butyl-1,1- dimethylindane et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique
IL122759A (en) METHOD OF DETERMINING THE DEGREE OF AGGREGATION OF THE betaA4 PEPTIDE
HUP0103649A3 (en) Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues and their use
IT1244880B (it) Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
AU6769294A (en) Optically-active, amphiphilic, water-soluble free-radical addition copolymers and their use in the resolution of racemic mixtures
IT8922485A0 (it) Copoliestereammide termotropica,procedimento per la sua preparazione e suo impiego
ITMI20011670A0 (it) Uso dell'r(-)flurbiprofen nella preparazione di un medicamento antipiretico
ITMI20001825A1 (it) Uso dell'r(-) flurbiprofen nella preparazione di un medicamento antipiretico

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *GLAXO GROUP LTD

Effective date: 20081121